221 related articles for article (PubMed ID: 31217475)
1. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.
Zhu XN; He P; Zhang L; Yang S; Zhang HL; Zhu D; Liu MD; Yu Y
Cell Death Dis; 2019 Jun; 10(7):486. PubMed ID: 31217475
[TBL] [Abstract][Full Text] [Related]
2. The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.
De S; Holvey-Bates EG; Mahen K; Willard B; Stark GR
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34795058
[TBL] [Abstract][Full Text] [Related]
3. F-box protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote hepatocellular carcinoma progression.
Tian X; Dai S; Sun J; Jin G; Jiang S; Meng F; Li Y; Wu D; Jiang Y
Oncotarget; 2015 Sep; 6(26):22767-75. PubMed ID: 26087183
[TBL] [Abstract][Full Text] [Related]
4. F-Box Protein FBXO22 Mediates Polyubiquitination and Degradation of CD147 to Reverse Cisplatin Resistance of Tumor Cells.
Wu B; Liu ZY; Cui J; Yang XM; Jing L; Zhou Y; Chen ZN; Jiang JL
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117675
[TBL] [Abstract][Full Text] [Related]
5. FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2.
Ma J; Wu Y; Cheng S; Yang W; Zhong L; Li Q; Fang L
Dig Dis Sci; 2023 May; 68(5):1913-1922. PubMed ID: 36515852
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
Liu M; Jiang L; Fu X; Wang W; Ma J; Tian T; Nan K; Liang X
Cancer Sci; 2018 Oct; 109(10):3055-3067. PubMed ID: 30033530
[TBL] [Abstract][Full Text] [Related]
7. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
Chen Z; Li JL; Lin S; Cao C; Gimbrone NT; Yang R; Fu DA; Carper MB; Haura EB; Schabath MB; Lu J; Amelio AL; Cress WD; Kaye FJ; Wu L
J Clin Invest; 2016 Jun; 126(6):2267-79. PubMed ID: 27140397
[TBL] [Abstract][Full Text] [Related]
8. SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence.
Johmura Y; Sun J; Kitagawa K; Nakanishi K; Kuno T; Naiki-Ito A; Sawada Y; Miyamoto T; Okabe A; Aburatani H; Li S; Miyoshi I; Takahashi S; Kitagawa M; Nakanishi M
Nat Commun; 2016 Feb; 7():10574. PubMed ID: 26868148
[TBL] [Abstract][Full Text] [Related]
9. FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis.
Guo F; Liu J; Han X; Zhang X; Lin T; Wang Y; Bai J; Han J
Int J Biol Sci; 2019; 15(3):647-656. PubMed ID: 30745851
[TBL] [Abstract][Full Text] [Related]
10. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
11. Mir-451 inhibits proliferation and migration of non-small cell lung cancer cells via targeting LKB1/AMPK.
Liu Y; Li H; Li LH; Tang JB; Sheng YL
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):274-280. PubMed ID: 31389598
[TBL] [Abstract][Full Text] [Related]
12. FBXO22 inhibits proliferation and metastasis of cervical cancer cells by mediating ubiquitination-dependent degradation of GAK.
Li S; Shi L; Wang Y; Zhang L; Chu S; Li M; Bai J; Zhu W
Exp Cell Res; 2023 Sep; 430(1):113719. PubMed ID: 37442264
[TBL] [Abstract][Full Text] [Related]
13. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
[TBL] [Abstract][Full Text] [Related]
14. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
15. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.
Dong LX; Sun LL; Zhang X; Pan L; Lian LJ; Chen Z; Zhong DS
Acta Pharmacol Sin; 2013 Feb; 34(2):314-8. PubMed ID: 23178462
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
[TBL] [Abstract][Full Text] [Related]
17. Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.
Yang R; Li SW; Chen Z; Zhou X; Ni W; Fu DA; Lu J; Kaye FJ; Wu L
J Natl Cancer Inst; 2019 Jul; 111(7):664-674. PubMed ID: 30423141
[TBL] [Abstract][Full Text] [Related]
18. LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
Whang YM; Park SI; Trenary IA; Egnatchik RA; Fessel JP; Kaufman JM; Carbone DP; Young JD
Oncogene; 2016 Feb; 35(7):856-66. PubMed ID: 26119936
[TBL] [Abstract][Full Text] [Related]
19. SCF
Bai J; Wu K; Cao MH; Yang Y; Pan Y; Liu H; He Y; Itahana Y; Huang L; Zheng JN; Pan ZQ
Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11754-11763. PubMed ID: 31138683
[TBL] [Abstract][Full Text] [Related]
20. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
